These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 35876374)

  • 21. Histomorphologic tumor regression and lymph node metastases determine prognosis following neoadjuvant radiochemotherapy for esophageal cancer: implications for response classification.
    Schneider PM; Baldus SE; Metzger R; Kocher M; Bongartz R; Bollschweiler E; Schaefer H; Thiele J; Dienes HP; Mueller RP; Hoelscher AH
    Ann Surg; 2005 Nov; 242(5):684-92. PubMed ID: 16244542
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Refining pathological evaluation of neoadjuvant therapy for adenocarcinoma of the esophagus.
    Noble F; Nolan L; Bateman AC; Byrne JP; Kelly JJ; Bailey IS; Sharland DM; Rees CN; Iveson TJ; Underwood TJ; Bateman AR
    World J Gastroenterol; 2013 Dec; 19(48):9282-93. PubMed ID: 24409055
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Residual tumor model in esophageal squamous cell carcinoma after neoadjuvant immunochemotherapy: Frequently involves the mucosa and/or submucosa.
    Gao L; Hong ZN; Wu L; Yang Y; Kang M
    Front Immunol; 2022; 13():1008681. PubMed ID: 36569913
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison of five tumor regression grading systems for gastric adenocarcinoma after neoadjuvant chemotherapy: a retrospective study of 192 cases from National Cancer Center in China.
    Zhu Y; Sun Y; Hu S; Jiang Y; Yue J; Xue X; Yang L; Xue L
    BMC Gastroenterol; 2017 Mar; 17(1):41. PubMed ID: 28292272
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Development and Validation of a Recurrence-Free Survival Prediction Model for Locally Advanced Esophageal Squamous Cell Carcinoma with Neoadjuvant Chemoradiotherapy.
    Zhou Y; He W; Guo P; Zhou C; Luo M; Liu Y; Yang H; Qin S; Leng X; Huang Z; Liu Y
    Ann Surg Oncol; 2024 Jan; 31(1):178-191. PubMed ID: 37751117
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Patterns and timing of recurrence in esophageal squamous cell carcinoma patients treated with neoadjuvant chemoradiotherapy plus esophagectomy.
    Nagaki Y; Motoyama S; Sato Y; Wakita A; Fujita H; Sasaki Y; Imai K; Minamiya Y
    BMC Cancer; 2021 Nov; 21(1):1192. PubMed ID: 34753448
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Classification of pathologic response to neoadjuvant therapy in esophageal and junctional cancer: assessment of existing measures and proposal of a novel 3-point standard.
    Donohoe CL; O'Farrell NJ; Grant T; King S; Clarke L; Muldoon C; Reynolds JV
    Ann Surg; 2013 Nov; 258(5):784-92; discussion 792. PubMed ID: 24045450
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prognostic significance of tumour regression grade after neoadjuvant chemoradiotherapy for a cohort of patients with locally advanced rectal cancer: an 8-year retrospective single-institutional study.
    Xu L; Cai S; Xiao T; Chen Y; Qiu H; Wu B; Lin G; Sun X; Lu J; Zhou W; Xiao Y
    Colorectal Dis; 2017 Jul; 19(7):O263-O271. PubMed ID: 28603932
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Role of pathological tumor regression grade of lymph node metastasis following neoadjuvant chemotherapy in locally advanced gastric cancer.
    Gao B; Zhao Z; Gao X; Zhang T; Zhang N; Zhang Y; Zhu Y
    Dig Liver Dis; 2024 Oct; 56(10):1768-1775. PubMed ID: 38811246
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tumor Regression Grade in Gastric Cancer After Preoperative Therapy.
    Ikoma N; Estrella JS; Blum Murphy M; Das P; Minsky BD; Mansfield P; Ajani JA; Badgwell BD
    J Gastrointest Surg; 2021 Jun; 25(6):1380-1387. PubMed ID: 32542556
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Lymph node station ratio: Revised nodal category for resected esophageal squamous cell carcinoma patients.
    Fu X; Liu Q; Luo K; Wen J; Yang H; Hu Y; Wang X; Lin P; Fu J
    J Surg Oncol; 2017 Dec; 116(7):939-946. PubMed ID: 28703872
    [TBL] [Abstract][Full Text] [Related]  

  • 32. College of American Pathologists Tumor Regression Grading System for Long-Term Outcome in Patients with Locally Advanced Rectal Cancer.
    Chen HY; Feng LL; Li M; Ju HQ; Ding Y; Lan M; Song SM; Han WD; Yu L; Wei MB; Pang XL; He F; Liu S; Zheng J; Ma Y; Lin CY; Lan P; Huang MJ; Zou YF; Yang ZL; Wang T; Lang JY; Orangio GR; Poylin V; Ajani JA; Wang WH; Wan XB
    Oncologist; 2021 May; 26(5):e780-e793. PubMed ID: 33543577
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Residual Cancer Volume Predicts Clinical Outcome in Patients With Esophageal Squamous Cell Carcinoma After Neoadjuvant Chemotherapy.
    Nakao R; Konishi E; Fujiwara H; Otsuji E; Yokota I; Urata Y; Yanagisawa A
    Int J Surg Pathol; 2019 Oct; 27(7):713-721. PubMed ID: 31203677
    [No Abstract]   [Full Text] [Related]  

  • 34. Lymph node ratio-based staging system for esophageal squamous cell carcinoma.
    Chen SB; Weng HR; Wang G; Zou XF; Liu DT; Chen YP; Zhang H
    World J Gastroenterol; 2015 Jun; 21(24):7514-21. PubMed ID: 26139998
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The Impact of Tumor Regression on Prognosis After Neoadjuvant Chemoradiotherapy in Surgically Treated Esophageal Adenocarcinoma.
    Crull DJ; Hogenes MCH; Hoekstra R; Hendriksen EM; van Det MJ; Kouwenhoven EA
    Ann Surg Oncol; 2022 Jun; 29(6):3658-3666. PubMed ID: 35094189
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Development and evaluation of the Newstage system: integrating tumor regression grade and lymph node status for improved prognostication in neoadjuvant treatment of gastric cancer.
    Chen M; Yu S; Chen C; Liang J; Zhou D
    World J Surg Oncol; 2024 Jan; 22(1):16. PubMed ID: 38195570
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Histomorphological tumor regression grading of esophageal carcinoma after neoadjuvant radiochemotherapy: which score to use?
    Hermann RM; Horstmann O; Haller F; Perske C; Christiansen H; Hille A; Schmidberger H; Füzesi L
    Dis Esophagus; 2006; 19(5):329-34. PubMed ID: 16984527
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Histological regression of squamous esophageal carcinoma assessed by percentage of residual viable cells after neoadjuvant chemoradiation is an important prognostic factor.
    Tong DK; Law S; Kwong DL; Chan KW; Lam AK; Wong KH
    Ann Surg Oncol; 2010 Aug; 17(8):2184-92. PubMed ID: 20217248
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prognostic differences in 8th edition TNM staging of esophagogastric adenocarcinoma after neoadjuvant treatment.
    Sisic L; Blank S; Nienhüser H; Dorr S; Haag GM; Jäger D; Bruckner T; Müller-Stich BP; Ott K; Büchler MW; Ulrich A; Schmidt T
    Eur J Surg Oncol; 2018 Oct; 44(10):1646-1656. PubMed ID: 30082176
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Application of the 8th edition of the AJCC yTNM staging system shows improved prognostication in a single center cohort of esophageal carcinomas.
    Kröll D; Noser L; Erdem S; Storni F; Arnold D; Dislich B; Zlobec I; Candinas D; Seiler CA; Langer R
    Surg Oncol; 2018 Mar; 27(1):100-105. PubMed ID: 29549896
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.